Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 9, 2022JAMA DermatologyOpen Access

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEric L. SimpsonOregon Health & Science University
Kim Papp
Kim PappUniversity of TorontoABAndrew BlauveltUniversity of Geneva

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Simpson et al. (2022) studied this question.

synapsesocial.com/papers/6a725e2735aa2c282ce33895https://doi.org/10.1001/jamadermatol.2022.0029
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis2016 · 2,107 citations
  2. 2Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results2021 · 129 citations
  3. 3Systemic Treatment of Adult Atopic Dermatitis: A Review2016 · 157 citations
  4. 4In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)2018 · 392 citations